TR-107 is a chemical activator of the human mitochondrial protease ClpP with an EC50 of 140 nM. It exhibits excellent potency and specificity in the research of triple-negative breast cancer (TNBC) cell models.

TR-107 is a chemical activator of the human mitochondrial protease ClpP with an EC50 of 140 nM. It exhibits excellent potency and specificity in the research of triple-negative breast cancer (TNBC) cell models.

TR-107 is a chemical activator of the human mitochondrial protease ClpP with an EC50 of 140 nM. It exhibits excellent potency and specificity in the research of triple-negative breast cancer (TNBC) cell models.

TR-107 is a chemical activator of the human mitochondrial protease ClpP with an EC50 of 140 nM. It exhibits excellent potency and specificity in the research of triple-negative breast cancer (TNBC) cell models.

YD23 is a PROTAC which induces the degradation of SMARCA2. It reduces chromatin accessibility in SMARCA4-deficient cells, affecting gene enhancers related to cell cycle and growth regulation, which leads to the downregulation of several cell cycle genes. It also selectively inhibits the growth of SMARCA4 mutant lung cancer cells in vitro.

YD23 is a PROTAC which induces the degradation of SMARCA2. It reduces chromatin accessibility in SMARCA4-deficient cells, affecting gene enhancers related to cell cycle and growth regulation, which leads to the downregulation of several cell cycle genes. It also selectively inhibits the growth of SMARCA4 mutant lung cancer cells in vitro.

YD23 is a PROTAC which induces the degradation of SMARCA2. It reduces chromatin accessibility in SMARCA4-deficient cells, affecting gene enhancers related to cell cycle and growth regulation, which leads to the downregulation of several cell cycle genes. It also selectively inhibits the growth of SMARCA4 mutant lung cancer cells in vitro.

YD23 is a PROTAC which induces the degradation of SMARCA2. It reduces chromatin accessibility in SMARCA4-deficient cells, affecting gene enhancers related to cell cycle and growth regulation, which leads to the downregulation of several cell cycle genes. It also selectively inhibits the growth of SMARCA4 mutant lung cancer cells in vitro.

JBJ-09-063 hydrochloride is a mutant-selective allosteric inhibitor of EGFR with IC50 values of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S, respectively. JBJ-09-063 hydrochloride significantly inhibits the phosphorylation of EGFR, Akt, and ERK1/2.

JBJ-09-063 hydrochloride is a mutant-selective allosteric inhibitor of EGFR with IC50 values of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S, respectively. JBJ-09-063 hydrochloride significantly inhibits the phosphorylation of EGFR, Akt, and ERK1/2.